{"id":38374,"date":"2025-08-20T10:04:35","date_gmt":"2025-08-20T08:04:35","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=38374"},"modified":"2025-08-15T11:56:55","modified_gmt":"2025-08-15T09:56:55","slug":"neue-aspekte-zum-suizidrisiko-unter-gabapentinoiden-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2025\/neue-aspekte-zum-suizidrisiko-unter-gabapentinoiden-cme","title":{"rendered":"Neue Aspekte zum Suizidrisiko unter Gabapentinoiden [CME]"},"content":{"rendered":"<p>Gabapentinoide (Gabapentin und Pregabalin = GabaP) sind zugelassen f\u00fcr die Therapie von Epilepsie, neuropathischen Schmerzen und generalisierter Angstst\u00f6rung. Mehr als 50% der Verschreibungen gehen aber auf einen \u201eOff-Label-Use\u201c zur\u00fcck , wie \u201eRestless-Legs\u201c-Syndrom, Multiple Sklerose, diverse Schmerzsyndrome, Schlaflosigkeit, schwere Depression und bipolare St\u00f6rungen ,\u00a0. \u00dcber GabaP und deren Risiken haben wir mehrmals berichtet . Bemerkenswerterweise hat [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gabapentinoide (Gabapentin und Pregabalin = GabaP) sind zugelassen f\u00fcr die Therapie von Epilepsie, neuropathischen Schmerzen und generalisierter Angstst\u00f6rung. Mehr als 50% der Verschreibungen gehen aber auf einen \u201eOff-Label-Use\u201c zur\u00fcck , wie \u201eRestless-Legs\u201c-Syndrom, Multiple Sklerose, diverse Schmerzsyndrome, Schlaflosigkeit, schwere Depression und bipolare St\u00f6rungen ,\u00a0. \u00dcber GabaP und deren Risiken haben wir mehrmals berichtet . Bemerkenswerterweise hat [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[236,6238,1384,3816,6239],"class_list":["post-38374","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-gabapentin","tag-gabapentinoide","tag-pregabalin","tag-suizid","tag-suizidrisiko"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=38374"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38374\/revisions"}],"predecessor-version":[{"id":38375,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38374\/revisions\/38375"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=38374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=38374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=38374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}